Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

David A. Hyman, MD, JD, on Inclusive Shared Savings

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Welcome and Introduction to Vi3C

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Mar
08
Today In Oncology
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
Cumulative Incidence of Advanced Breast Cancer in Japanese Women Aged 40 to 49 Years With Addition of Ultrasonography to Mammography Screening
HPV Vaccination Protection From Cervical Cancer Sustained Long Term
Five-Year Outcomes With First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma
FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo